Differential Access to Direct Acting Antivirals (DAAs) Across Federal, State, Commercial, and Manufacturer Patient Assistance Programs (MPAP)
AASLD LiverLearning®, Jane Giang, 144651
Treatment of chronic HCV infection with the new direct acting antivirals (DAAs): a Real World experience in Brazil.
AASLD LiverLearning®, Hugo Cheinquer, 144908
Effectiveness and security of 3D/2D treatment in HCV/HIV coinfected cirrhotic patients
AASLD LiverLearning®, MIGUEL ANGEL VON WICHMANN, 144909
Comparative Efficacy of an Intensified Re-Vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected with HIV (CORE-HIV): A Randomized Controlled Trial. Interim Analysis.
AASLD LiverLearning®, Jose Ignacio Vargas, 144667
Spontaneous Bacterial Peritonitis in cirrhosis: a Prospective Multicenter Study of Clinical, Microbiological characteristics and Predictors of 6 months Survival
AASLD LiverLearning®, Dimitrios Samonakis, 144924
Infection with multi-drug resistant organisms is associated with increased mortality in patients listed for liver transplantation.
AASLD LiverLearning®, Rosalie C. Oey, 144925
Quantitative Hepatitis B Surface Antigen Does Not Reliably Identify Patients with Active Hepatitis D Virus Infection
AASLD LiverLearning®, Matthew Sadler, 144683
Drug resistant infections in hospitalized patients with cirrhosis are nosocomial and associated with renal and respiratory failure: Results from NACSELD.
AASLD LiverLearning®, Jasmohan S. Bajaj, 144940
Improved short-term survival in patients with Acute-on-Chronic Liver Failure (ACLF) in extremis with a combination therapy approach
AASLD LiverLearning®, Gaurav Pande, 144941
Risk for progressing to immune active (IA) phase chronic hepatitis B virus infection (CHB) among Alaska Native (AN) persons in the inactive carrier (IC) and indeterminate CHB infection phases — Alaska, 2001-2014.
AASLD LiverLearning®, Prabhu Gounder, 144698
Hepatitis B surface antigen titer is a good indicator of durable viral response after off-treatment of entecavir for chronic hepatitis B
AASLD LiverLearning®, Hanah Lee, 144699
Oral Rifaximin Soluble Solid Dispersion Immediate-Release 40 mg Prevents Development of Cirrhosis-Related Complications: a Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial
AASLD LiverLearning®, Jasmohan S. Bajaj, 144956
Assess outcome of Slow low-dose continuous albumin,Furosemide with or without Terlipressin SIFA(T) infusion in patients of cirrhosis with refractory ascites
AASLD LiverLearning®, Gaurav Pande, 144957
Effect of Glucocorticoid on Hepatitis B Virus Reactivation in HBsAg-positive Rheumatoid Arthritis Patients undergoing Biologics Treatment
AASLD LiverLearning®, Yi-Hsiang Huang, 144715
The SNPs of HLA-DP are associated with HBsAg levels in chronic HBV infection
AASLD LiverLearning®, Ochi Yuka, 144716
Urinary NGAL biomarker predicts non response to therapy with albumin and terlipressin in patients with hepatorenal syndrome
AASLD LiverLearning®, Rafael Ximenes, 144972
TLR-9 rs187084-dependent reduction of inflammatory and sympathetic responses to bacterial translocation in patients with decompensated cirrhosis
AASLD LiverLearning®, Paula Piñero Romero, 144973
Diagnostic performance of APRI, FIB-4 and Fibroscan for assessment of hepatic fibrosis in chronic hepatitis B patients receiving oral antiviral therapy; 7-year real life data
AASLD LiverLearning®, Iftihar Köksal, 144731
Validation of a Mortality Risk Score to assess the Long-Term Prognosis of Chronic Hepatitis B Patients
AASLD LiverLearning®, Willem Pieter Brouwer, 144732
Safety and efficacy of prolonged low dose thrombolysis for acute non-malignant and non-cirrhotic splanchnic venous thrombosis
AASLD LiverLearning®, Pathik Parikh, 144988
The pan caspase inhibitor Emricasan improves the hepatic microcirculatory dysfunction of CCl4-cirrhotic rats leading to portal hypertension amelioration and cirrhosis regression
AASLD LiverLearning®, Jordi Gracia-Sancho, 144989
Intrahepatic persistence of hepatitis B virus covalently closed circular DNA (cccDNA) after 3 to 5 years of telbivudine therapy for chronic hepatitis B (CHB)
AASLD LiverLearning®, Fabien Zoulim, 144747
Comparison Of Markers Of Bone Turnover Demonstrates Less Changes In CHB Patients Receiving Tenofovir Alfenamide (TAF) Compared with Tenofovir disoproxil fumarate (TDF)
AASLD LiverLearning®, Wan-Long Chuang, 144748
Bowel wall thickness and elasticity, Intestinal Permeability and Serum Inflammatory Mediators in Patients with Decompensated Liver Cirrhosis
AASLD LiverLearning®, Sang Hyuk Lee, 145004
Impact of Antiviral Nucleotide Analogues on Age-Dependent Decline in Renal Function
AASLD LiverLearning®, Prowpanga Udompap, 144763
A Retrospective Study on the Clearance Rate of Hepatitis B Surface Antigen with Antivirus Treatment in 1 to 7 years old Children with HBeAg-positive Chronic Hepatitis B
AASLD LiverLearning®, Zhu Shishu, 144764
Tenofovir disoproxil fumarate Monotherapy is superior to Entecavir-adefovir Combination in Suboptimal Responder for Lamivudine-adefovir Therapy in Chronic Hepatitis B Patients with rt204I/V Mutation: a 96-Week Prospective Multicenter Trial
AASLD LiverLearning®, Sae Hwan Lee, 144780
A randomized study comparing tenofovir dispoxil fumarate and entecavir hydrate in Japanese patients with treatment naïve chronic hepatitis B
AASLD LiverLearning®, Wataru Sugiura, 144781
Understanding the unmet need in Autoimmune Hepatitis - The United Kingdom AIH Study (UK-AIH)
AASLD LiverLearning®, Lin Lee Wong, 144539
Characterization Of Changes In FibroTest Values During Treatment With Tenofovir Alfenamide (TAF) Or tenofovir disproxil fumarate (TDF) In Patients With CHB
AASLD LiverLearning®, Namiki Izumi, 144796
Liver stiffness and virologic outcomes after introducing tenofovir as part of antiretroviral therapy in lamivudine-experienced adults with HIV and hepatitis B virus (HBV) co-infection in Ghana: four-year follow up of the prospective HEPIK cohort
AASLD LiverLearning®, Alexander Stockdale, 144797
UK-AIH - Highlighting the need for standardization of treatment in autoimmune hepatitis
AASLD LiverLearning®, Lin Lee Wong, 144555
The influence of clinical significant portal hypertension (stage Baveno 2) on safety, tolerability and efficacy of paritaprevir, ritonavir, ombitasvir, dasabuvir and ribavirin (PrOD+R) in a real-world large cohort of genotype 1b HCV liver cirrhosis patien
AASLD LiverLearning®, Anca Trifan, 144812
Predictors of Sustained Virological Response (SVR) after Direct Acting Antiviral (DAA) treatment for Hepatitis C: meta-analysis of 55 studies in 11,419 patients
AASLD LiverLearning®, Bryony Simmons, 144813
Advanced glycation end products and dysregulated RAGE/AGER1 induce proinflammatory and fibrogenic signaling in NASH via NOX4
AASLD LiverLearning®, Ali Dehnad, 144571
Current treatment options with direct acting antivirals in HCV genotype 3 infections - still room for improvement? Results from the German multicenter GECCO cohort.
AASLD LiverLearning®, Julian Schulze zur Wiesch, 144828
Effect of daclatasvir and asunaprevir combination therapy for chronic hepatitis or compensated cirrhosis by HCV genotype 1b infection with RAV negative population; from real world data.
AASLD LiverLearning®, Masatoshi Ishigami, 144829
Disruption of Heat Shock Transcription Factor 1 (HSF1) reveals its essential role in protection from liver inflammation and fibrosis
AASLD LiverLearning®, Asmita Choudhury, 144587
Regression of liver fibrosis following Sustained Viral response (SVR) with Interferon(IFN)-free HCV treatment
AASLD LiverLearning®, Barbara Menzaghi, 144844
The impact of IL28B polymorphism and HCV NS5A resistance associated variants on treatment response with ledipasvir and sofosbuvir regimen in Japanese real-life settings
AASLD LiverLearning®, Hitomi Sezaki, 144845
Endoscopic Screening for large varices: increase in MELD score more predictive of variceal growth than calendar year
AASLD LiverLearning®, Sakkarin Chirapongsathorn, 144603
Premature Discontinuation of Direct Acting Antiviral (DAA) Therapy in Patients with Chronic Hepatitis C Virus (HCV) in Real World Clinical Practice
AASLD LiverLearning®, Jasmine Hanifi, 144860
Sofosbuvir plus Ribavirin for difficult to treat HCV-2 : improved efficacy with extended treatment duration
AASLD LiverLearning®, Sara Piovesan, 144861
Extensive Economic and Quality of Life Burden of Viral Hepatitis (VH): The Data from the U.S. Medical Expenditure Panel Survey (MEPS)
AASLD LiverLearning®, Zobair Younossi, 144619
Baseline and post-treatment hepatitis C NS5A resistance analysis in relapsed patients from a multicentric real life cohort of 2740 patients exposed to NS5A inhibitor
AASLD LiverLearning®, Philippe Halfon, 144876
Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: the Canadian National Experience.
AASLD LiverLearning®, Bandar Aljudaibi, 144877
Patient reported assessment of different diagnostic imaging tests for liver disease - visual representation and ownership of results improves understanding.
AASLD LiverLearning®, Andrew McKay, 144635
Factors that influence the improvement of liver albumin synthesis during interferon-free sofosbuvir-based therapy of chronic hepatitis C virus infection
AASLD LiverLearning®, Akira Kawano, 144892
Efficacy of direct-acting antiviral agents for treatment of HCV genotype 1 infection in Hispanics: data from a real-world cohort.
AASLD LiverLearning®, Andres Carrion, 144893
Module 1: Anatomy and Physiology of the Liver
AASLD LiverLearning®, Tamar Taddei, 119131
Management of Hepatic Encephalopathy
AASLD LiverLearning®, Jasmohan Bajaj, 154717
Surgery Risk Assessment in the Cirrhotic Patient
AASLD LiverLearning®, Patrick Northup, 154716
Update in Wilson Disease
AASLD LiverLearning®, Eve Roberts, 154715
Pegylated interferon alfa-2a (40KD) is efficacious and safe in treatment of HBeAg-positive children with chronic hepatitis B: Peg-B-Active study
AASLD LiverLearning®, Stefan Wirth, 155355
Hepatology Associates Course
AASLD LiverLearning®, Session Speakers, 155769
HIV, HBV, HCV Coinfections
AASLD LiverLearning®, Douglas Dieterich, 154676
Approach to the Patient with Iron Overload
AASLD LiverLearning®, Kris Kowdley, 154675
Adult Living Donor Liver Transplant: Donor and Recipient Considerations
AASLD LiverLearning®, Rebecca Duke, 154674
Awarded Poster Presentation
AASLD LiverLearning®, Anna Hefner, 154673
iPSC and Disease Modeling in the Liver
AASLD LiverLearning®, Ludovic Vallier, 154691
The Impact of Cirrhotic PVT on Liver Transplant: A Medical Perspective
AASLD LiverLearning®, Nicolas Intagliata, 154701
Complications of Cholestatic Liver Diseases
AASLD LiverLearning®, Cynthia Levy, 154672
iPSCs and Correction of A1AT Deficiency
AASLD LiverLearning®, Andrew Wilson, 154690
Cholangiocytes From iPSC
AASLD LiverLearning®, Romina Fiorotto, 155708
Treatment of PVT in Cirrhosis: Who, When and How
AASLD LiverLearning®, Juan Carlos Garcia-Pagan, 154700
Etiology of Liver Disease: Does it Make a Clinical Difference?
AASLD LiverLearning®, Jordi Bruix, 154712
Hepatocytes From iPSC
AASLD LiverLearning®, Holger Willenbring, 154688
Diagnosis and Natural History of PVT In Cirrhosis
AASLD LiverLearning®, Dominique Valla, 154699
Statins and Metformin as Chemoprevention for HCC
AASLD LiverLearning®, Lewis Roberts, 154711
Panel Discussion
AASLD LiverLearning®, Session Speakers, 155768
Future Landscape With HCV Therapy
AASLD LiverLearning®, Fred Poordad, 154669
Session II: Epidemiology and Clinical Insights
AASLD LiverLearning®, Gregory Gores, 154709
Liver Transplantation for NASH Associated HCC
AASLD LiverLearning®, Kimberly Ann Brown, 154710
Cirrhosis – Beyond Portal Hypertension
AASLD LiverLearning®, Lucy Mathew, 154668
Engineering of the Liver via iPSC
AASLD LiverLearning®, Takanori Takebe, 154685
Does Prophylactic Anticoagulation Alter the Course of Cirrhosis? Lessons from Prophylactic Trials
AASLD LiverLearning®, ERICA VILLA, 154698
Natural History: The Magnitude of the Problem from Hepatology Clinic Perspective
AASLD LiverLearning®, Augusto Villanueva, 154708
Parenchymal Extinction in 2016: What is the Human Evidence?
AASLD LiverLearning®, Ian R. Wanless, 154697
Management of Metabolic Syndrome and NASH
AASLD LiverLearning®, Rohit Loomba, 154667
Induced Pluripotent Stem Cells in the Future of Gastroenterology/Hepatology
AASLD LiverLearning®, Stephen Duncan, 154684
Diabetes Associated HCC: The Molecular Profile
AASLD LiverLearning®, Jessica Zucman-Rossi, 154707
Coagulation, Thrombin, Fibrosis and Inflammatory Pathways in the Liver
AASLD LiverLearning®, James Luyendyk, 154696
NAFLD Promotes HCC by Causing CD4(+)T Cell Depletion
AASLD LiverLearning®, Tim Greten, 154706
Developmental Biology: The Foundation for Gastrointestinal Tissue Engineering
AASLD LiverLearning®, James Wells, 154681
Hepatology Associates Course: Session I
AASLD LiverLearning®, Lisa Richards, 154664
Managing Alcoholic Hepatitis
AASLD LiverLearning®, Vijay Shah, 154666
Cirrhosis as a Prothrombotic State: Overview and Update
AASLD LiverLearning®, Ton Lisman, 154695
A Randomized, Prospective, Comparative Study about Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis
AASLD LiverLearning®, Wang Yong Choi, 144137
Development of a Novel Circulating Tumor Cells Isolation System in Patients with Hepatocellular Carcinoma Using a Microcavity Array
AASLD LiverLearning®, Kazuto Takahashi, 144153
ALBI-T: A Score Based on Albumin, Bilirubin and TNM Stratifies Patients with Child A Cirrhosis and Hepatocellular Carcinoma
AASLD LiverLearning®, Imam Waked, 144169
Changes in tissue and blood biomarkers upon exposure to sorafenib in patients with resectable HCC: translational evaluation in the BIOSHARE trial
AASLD LiverLearning®, Valérie Paradis, 144185
Impact of Age, Gender, and Race/Ethnicity on Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma in the U.S.
AASLD LiverLearning®, Vicky Bhagat, 144201
Defining Optimal Follow-up Intervals for Hepatocellular Carcinoma: What Should the Cost-effective Standard Be?
AASLD LiverLearning®, Janice Jou, 144217
The Expression of SALL4 and Its Clinical Significance In Hepatocellular Carcinoma.
AASLD LiverLearning®, Zhiying Xin, 144233
Predictive factors of hepatocellular carcinoma and transplant-free survival in Chinese patients with primary biliary cholangitis
AASLD LiverLearning®, Ka Shing Cheung, 144249
When imaging and explant pathology conflict: defining the risk of false-positive hepatocellular carcinoma in recipients transplanted with T2 MELD exceptions
AASLD LiverLearning®, Therese Bittermann, 144265
Effects of Recipient Size and Allograft Type on Pediatric Liver Transplantation for Biliary Atresia
AASLD LiverLearning®, Sophoclis Alexopoulos, 144281
Therapeutic targeting of Hsp90 alleviates liver macrophage-specific NLRP3 inflammasome activation in alcoholic liver injury
AASLD LiverLearning®, Danielle Bullock, 144089
Differential regulation of human UDP-glucuronosyltransferases (UGTs) during chronic ethanol exposure in a humanized transgenic UGT1A mouse model
AASLD LiverLearning®, Steffen Landerer, 144105
Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver lesions in mice
AASLD LiverLearning®, Laura WRZOSEK, 144121